Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma.

Cancers (Basel) · 2024 · PMC11394608 · PMID 39272905

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, within the phase I trial for SHR-1701, aggregated p-SMAD2 levels across all cancer subtypes (advanced solid tumors) showed a trend towards increased ORR with high baseline SMAD-2 levels [ 79 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.